BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and remains...
BC Week In Review | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on solid tumor indications where it sees larger market...
BC Extra | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Extra | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million), one of the largest European VC funds focused on life sciences ever, according to BioCentury’s BCIQ database. The fund...
BioCentury | Feb 6, 2018
Finance

Stepping up in Europe

After closing one of Europe’s largest ever life sciences VC funds, Edmond de Rothschild Investment Partners now has the firepower to follow portfolio companies longer and put more capital to work in a wider variety...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Week In Review | Dec 14, 2017
Clinical News

Erytech's Graspa misses in Phase IIb AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia (AML) in patients ineligible for...
BC Extra | Dec 8, 2017
Clinical News

Erytech sinks after Graspa miss in AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia in...
Items per page:
1 - 10 of 81
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and remains...
BC Week In Review | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on solid tumor indications where it sees larger market...
BC Extra | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on...
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Extra | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million), one of the largest European VC funds focused on life sciences ever, according to BioCentury’s BCIQ database. The fund...
BioCentury | Feb 6, 2018
Finance

Stepping up in Europe

After closing one of Europe’s largest ever life sciences VC funds, Edmond de Rothschild Investment Partners now has the firepower to follow portfolio companies longer and put more capital to work in a wider variety...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Week In Review | Dec 14, 2017
Clinical News

Erytech's Graspa misses in Phase IIb AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia (AML) in patients ineligible for...
BC Extra | Dec 8, 2017
Clinical News

Erytech sinks after Graspa miss in AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia in...
Items per page:
1 - 10 of 81